Biogen
BIIB
112,94 €
Share price
-0.24%
Change (1 day)
-45.64%
Change (1 year)
Categories
Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
Biogen (BIIB) - Cash on Hand
Cash on Hand as of March 2025 : €2.20 Billion
According to Biogen's latest financial reports the company has €2.20 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Biogen - Cash on Hand chart (from 1996 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | €2.28 B | 140.31% |
| 2023-12-31 | €0.94 B | -79.18% |
| 2022-12-31 | €4.56 B | 35.85% |
| 2021-12-31 | €3.35 B | 58.22% |
| 2020-12-31 | €2.12 B | -46.89% |
| 2019-12-31 | €3.99 B | 29.19% |
| 2018-12-31 | €3.09 B | 0.59% |
| 2017-12-31 | €3.07 B | -33.93% |
| 2016-12-31 | €4.65 B | 48.42% |
| 2015-12-31 | €3.13 B | 106.65% |
| 2014-12-31 | €1.51 B | 71.38% |
| 2013-12-31 | €0.88 B | -31.34% |
| 2012-12-31 | €1.28 B | -0.95% |
| 2011-12-31 | €1.30 B | 43.38% |
| 2010-12-31 | €0.90 B | 2.94% |
| 2009-12-31 | €0.88 B | -8.11% |
| 2008-12-31 | €0.95 B | 18.43% |
| 2007-12-31 | €0.81 B | 18.48% |
| 2006-12-31 | €0.68 B | -4.74% |
| 2005-12-31 | €0.71 B | 365.13% |
| 2004-12-31 | €0.15 B | -38.26% |
| 2003-12-31 | €0.25 B | -66.82% |
| 2002-12-31 | €0.75 B | -16.61% |
| 2001-12-31 | €0.90 B | 24.75% |
| 2000-12-31 | €0.72 B | 11.37% |
| 1999-12-31 | €0.65 B | 49.32% |
| 1998-12-31 | €0.43 B | 17.46% |
| 1997-12-31 | €0.37 B | 36.94% |
| 1996-12-31 | €0.27 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | €7.48 B | 239.07% | 🇺🇸 USA |
 Gilead Sciences GILD | €6.73 B | 205.05% | 🇺🇸 USA |
 AbbVie ABBV | €4.39 B | 99.21% | 🇺🇸 USA |
 Pfizer PFE | €14.71 B | 566.44% | 🇺🇸 USA |
 Johnson & Johnson JNJ | €32.96 B | 1,392.55% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | €7.95 M | -99.64% | 🇺🇸 USA |
 Sanofi SNY | €7.34 B | 232.73% | 🇫🇷 France |
 Bio-Rad Laboratories BIO | €1.41 B | -36.10% | 🇺🇸 USA |
 Illumina ILMN | €1.05 B | -52.39% | 🇺🇸 USA |
 Qiagen QGEN | €0.81 B | -62.92% | 🇳🇱 Netherlands |